OBSIDIAN THERAPEUTICS, INC. Operating Expenses
OBSIDIAN THERAPEUTICS, INC. (OBX) reported Operating Expenses of $26.14 million for the 3-month period ending 2026-06-30, per its S-1 filed 2026-08-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-28
- OBSIDIAN THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $26.14M, a 7.50% decline year-over-year.
- OBSIDIAN THERAPEUTICS, INC. operating expenses for the quarter ending 2025-06-30 was $28.26M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 12 month |
|---|---|---|---|
| 2026-06-30 | $26.14M S-1 · filed 2026-08-28 | $46.42M S-1 · filed 2026-08-28 | |
| 2025-12-31 | $105.67M S-1 · filed 2026-08-28 | ||
| 2025-06-30 | $28.26M S-1 · filed 2026-08-28 | $54.86M S-1 · filed 2026-08-28 | |
| 2024-12-31 | $91.25M S-1 · filed 2026-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |